Will demand for EBM remain a mostly stagnant but fascinating niche or is now the time to buy for a bright and soon to resume rapid growth future?
Some years ago, when it was also “about to explode” I took a position in Arcam. It seems to be the stock that’s always “about” to get there but never arrives. This has been going on just like this for years. The story is great. They seem to be doing good things. They make great, sensible acquisitions. It just never gets there.
Unfortunately they remind me of those IPO’s where management figures they can just keep raising money and they never have to actually make any. I may be completely wrong, and they’ll take off next quarter, but I haven’t seen any signs that it’s really happening.
Saul